Loss in quality-adjusted life years was obtained using the 'under the curve' method and regression predictions. For each clinical stage (IA-IV), total costs per case from diagnosis to one year after final discharge were extrapolated based on inpatient records, responses to the telephone interview, and recommendation on outpatient follow-ups by Chinese cervical cancer treatment guidelines. Direct medical expenditures were converted to opportunity costs of care using cost-to-charge ratios obtained from hospital financial reports.
2019 with a 40% random draw of patients to obtain direct non-medical costs and indirect costs associated with inpatients, costs associated with outpatient visits, and changes in quality of life status using the EQ-5D-5L instrument. A telephone interview with four modules was conducted in Jun.-Jul. METHODS:Inpatient records of cervical cancer patients admitted to the largest cancer hospital in Henan province between Jan. This study adopted a societal perspective and investigated costs and quality of life changes associated with cervical cancer from diagnosis to one year after final discharge in Henan province, China.
To inform immunization policy, understanding the economic burden of the disease is necessary. Human papillomavirus (HPV) vaccines are expensive and not yet centrally funded. Morgan Stanley, BofA Securities, CICC, Tiger Brokers, and Snowball Securities were set to be the joint bookrunners on the deal.BACKGROUND:In China, the disease burden of cervical cancer remains substantial. It had planned to list on the Nasdaq under the symbol LDOC. The Beijing, China-based company was founded in 2014 and booked $154 million in sales for the 12 months ended March 31, 2021. The company's product suite includes a digital continuous care platform for patients with critical diseases, an AI-enabled curation system for longitudinal medical data, and a precision life sciences platform for clinical research. So far this year, 31 Chinese issuers have raised $12.3 billion in US IPOs, more than all of last year, representing roughly 15% of the US IPO market by deal count and proceeds.īacked by Alibaba Health, LinkDoc Technology provides a platform that structures cancer patient data to enable precision medicine and personalized care. Days after DiDi Global's ( DIDI) $4.4 billion US IPO, the regulator announced that it was pulling DiDi's app from the app store until it came under compliance with certain data security requirements, causing the stock to crash. The news comes amid China's latest crackdown of its domestic internet companies, which has most recently focused on US listings. On Wednesday, LinkDoc filed an amendment where it added risks related to China's new capital markets regulation and oversight, which had been issued by the country's regulator the day before. It had filed to raise $200 million by offering 10.8 million shares at a price range of $17.50 to $19.50. Insiders and anchor investors had indicated an interest in buying 58% of the deal. The company had been expected to price its IPO on Thursday night. LinkDoc Technology, a Chinese healthcare data company specializing in oncology patients, postponed its IPO on Thursday.
0 kommentar(er)
